Skip to main content

Table 2 Inclusion and characteristics of progression criteria by application stage and outcome

From: Inclusion of progression criteria in external randomised pilot trials: a cross-sectional study of funding applications submitted to the NIHR Research for Patient Benefit Programme

 

Outline application (Stage 1)

Full application (Stage 2)

Total

Invited

Rejected

Total

Awarded

Rejected

Progression criteria reporting

(n = 95)

(n = 52)a

(n = 43)

(n = 49)a

(n = 35)

(n = 14)

 Yes

48 (51%)

24 (46%)a

24 (56%)

36 (73%)

26 (74%)

10 (71%)

  Stipulated in Stage 1 and Stage 2

N/A

N/A

N/A

23 (65%)a

17 (65%)

6 (60%)

  Stipulated in stage two only

N/A

N/A

N/A

13 (36%)

9 (35%)

4 (40%)

 No

47 (49%)

28 (54%)

19 (44%)

13 (27%)

9 (26%)

4 (29%)

Characteristics of progression criteria

(n = 48)

(n = 24)

(n = 24)

(n = 36)

(n = 26)

(n = 10)

Format

  Distinct threshold / STOP-GO

18 (38%)

8 (33%)

10 (42%)

10 (27%)

9 (35%)

1 (10%)

  Distinct threshold / STOP-GO +b

15 (31%)

8 (33%)

7 (29%)

11 (31%)

9 (35%)

2 (20%)

  Traffic light system / STOP-AMEND-GO

5 (10%)

3 (13%)

2 (8%)

8 (22%)

3 (12%)

5 (50%)

  Traffic light system / STOP-AMEND-GO +b

4 (8%)

2 (8%)

2 (8%)

5 (14%)

3 (12%)

2 (20%)

  Non-numerical

6 (13%)

3 (13%)

3 (13%)

2 (6%)

2 (8%)

0 (0%)

Presentation

  Text

45 (94%)

23 (96%)

22 (92%)

32 (89%)

23 (88%)

9 (90%)

  Table

3 (6%)

1 (4%)

2 (8%)

4 (11%)

3 (12%)

1 (10%)

Areas of feasibility informing progression criteriac

  Recruitment

41 (85%)

22 (92%)

19 (79%)

31 (86%)

21 (81%)

10 (100%)

  Retention

27 (56%)

13 (54%)

14 (58%)

24 (67%)

16 (62%)

8 (80%)

  Acceptability of intervention or trial (participants)

19 (40%)

9 (38%)

10 (42%)

15 (42%)

10 (38%)

5 (50%)

  Data completion or missing data

16 (33%)

7 (29%)

9 (38%)

11 (31%)

7 (27%)

4 (40%)

  Non/compliance or adherence (participants)

13 (27%)

4 (17%)

9 (38%)

13 (36%)

11 (42%)

2 (20%)

  Consent or refusal rate

9 (19%)

4 (17%)

5 (21%)

6 (17%)

6 (23%)

0 (0%)

  Acceptability of intervention or trial (non-participants)

8 (17%)

5 (21%)

3 (13%)

11 (31%)

8 (31%)

3 (30%)

  Intervention fidelity

7 (15%)

1 (4%)

6 (25%)

9 (25%)

7 (27%)

2 (20%)

  Safety or adverse events

6 (13%)

5 (21%)

1 (4%)

7 (19%)

6 (23%)

1 (10%)

  Determine/estimate definitive trial sample size

6 (13%)

4 (17%)

2 (8%)

4 (11%)

4 (15%)

0 (0%)

  Completion or withdrawal

5 (10%)

2 (8%)

3 (13%)

4 (11%)

4 (15%)

0 (0%)

  Randomisation

5 (10%)

1 (4%)

4 (17%)

3 (8%)

2 (8%)

1 (10%)

  Other

35 (73%)

18 (75%)

17 (71%)

31 (86%)

23 (88%)

8 (80%)

Qualitative research informs progression criteria

  Yes

20 (42%)

10 (42%)

10 (42%)

18 (50%)

12 (46%)

6 (60%)

  No

18 (38%)

8 (33%)

10 (42%)

14 (39%)

11 (42%)

3 (30%)

  No qualitative research component

10 (21%)

6 (25%)

4 (17%)

4 (11%)

3 (12%)

1 (1%)

Justification or rationale for progression criteria given

  Yes

9 (19%)

3 (13%)

6 (25%)

7 (19%)

5 (19%)

2 (20%)

  For some criteria

7 (15%)

5 (21%)

2 (9%)

5 (14%)

4 (15%)

1 (10%)

  No

32 (67%)

16 (67%)

16 (67%)

24 (67%)

17 (65%)

7 (70%)

Application details who decided on progression criteria

  Yes

1 (2%)

0 (0%)

1 (4%)

1 (3%)

0 (0%)

1 (10%)

  No

47 (98%)

24 (100%)

23 (96%)

35 (97%)

26 (100%)

9 (90%)

Application details who will assess progression criteria

  Yes

8 (17%)

3 (13%)

5 (21%)

9 (25%)

6 (23%)

3 (30%)

  No

40 (83%)

21 (88%)

19 (79%)

27 (75%)

20 (77%)

7 (70%)

  1. Percentages might not add up to 100 due to rounding
  2. 95 Stage 1 applications were included, 52 were invited to Stage 2, three were ineligible and 49 were included
  3. aThree applications that were invited following Stage 1 were subsequently ineligible at Stage 2; One of these applications included progression criteria at Stage 1
  4. b+ indicates additional considerations specified that are not in a STOP-GO or STOP-AMEND-GO format
  5. cAreas of feasibility that were given in ≥5 Stage 1 application outlines are listed; all others are categorised in ‘other’; multiple areas of feasibility might inform progression criteria in individual applications